ArticleWorld journal of urology2025
Risk classification by pathological and biochemical prognostic factors determined by extensive exploration for metastatic hormone sensitive prostate cancer.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.The Prostate · 2026Article
- Prognostic Value of the Postoperative Advanced Lung Cancer Inflammation Index in Patients with Prostate Cancer Undergoing Radical Prostatectomy.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine prognostic parameters, we extensively examined whether physical, biochemical, and histological factors were associated with clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients.
methodsA total 822 mHSPC patients were retrospectively investigated and examined the associations between prognosis and clinicopathological parameters including BMI, initial PSA level, TNM classification, Hb, Alb, CRP, AST, ALT, LDH, ALP, Gleason grade group, and EOD score.
resultsAccording to the CHAARTED criteria, 338 (41.1%) and 484 (58.9%) patients were classified into low- and high-volume disease, respectively. In univariate and multivariate analyses, Gleason grade group, Alb, CRP, LDH, and ALP were determined as significant predictors for both PFS and OS. When mHSPC patients were classified into three group including favorable (none of risk factors), intermediate (one or two risk factors) and poor (more than three risk factors) according to these four parameters, the survival curves were significantly stratified according to the risk classification. When the risk classification was applied on the patients with low- or high-volume disease in CHAARTED criteria, worse prognosis was found in poor risk group patients with low-volume disease and favorable prognosis was found in favorable risk group patients with high-volume disease.
conclusionThese results suggested that Gleason grade, CRP, LDH, and ALP were the independent predictors for mHSPC patients regardless of metastatic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.